美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

DAMORA THERAPEUT

23.05

+4.9127.07%

成交量：33.79万

成交额：718.94万

市值：13.89亿

市盈率：-0.15

高：23.18

开：17.81

低：17.66

收：18.14

52周最高：38.33

52周最低：2.01

股本：6,024.01万

流通股本：5,114.08万

量比：0.72

换手率：0.66%

股息：- -

股息率：- -

每股收益(TTM):-153.9532

每股收益(LYR):-18.5274

净资产收益率：-163.80%

总资产收益率：-16.46%

市净率：-7.90

市盈率(LYR):-1.24

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Galecto Inc旗下Damora计划于2026年中提交DMR-001新药临床试验申请概念验证数据预计2027年中公布

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/DMRA"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","market":"US","secType":"STK","nameCN":"DAMORA THERAPEUT","latestPrice":23.05,"timestamp":1774296000000,"preClose":18.14,"halted":0,"volume":337881,"delay":0,"changeRate":0.27067254685777287,"floatShares":51140800,"shares":60240100,"eps":-153.95322,"marketStatus":"盘前交易","change":4.91,"latestTime":"03-24 07:35:41 EDT","open":17.81,"high":23.18,"low":17.655,"amount":7189378.870683,"amplitude":0.304576,"askPrice":25.08,"askSize":100,"bidPrice":20.68,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-153.95322,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774359000000},"marketStatusCode":1,"adr":0,"listingDate":1603944000000,"exchange":"NASDAQ","adjPreClose":23.05,"postHourTrading":{"tag":"盘后","latestPrice":23.1644,"preClose":23.05,"latestTime":"19:10 EDT","volume":667,"amount":15430.0055,"timestamp":1774307401144,"change":0.1144,"changeRate":0.004963,"amplitude":0.004963},"volumeRatio":0.7245136542319823},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","floatShares":51140800,"roa":"-16.46%","roe":"-163.80%","lyrEps":-18.527432,"volumeRatio":0.7245136542319823,"shares":60240100,"dividePrice":0,"high":23.18,"amplitude":0.304576,"preClose":18.14,"low":17.655,"week52Low":2.01,"pbRate":"-7.90","week52High":38.3251,"institutionHeld":0,"latestPrice":23.05,"eps":-153.95322,"divideRate":0,"volume":337881,"delay":0,"ttmEps":-153.95322,"open":17.81,"prevYearClose":23.01,"prevWeekClose":18.14,"prevMonthClose":29.58,"prevQuarterClose":23.01,"fiveDayClose":24.98,"twentyDayClose":29.78,"sixtyDayClose":29.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-19","symbol":"DMRA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"DMRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-2.36},{"market":"US","date":"2025-08-05","symbol":"DMRA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-2.6},{"market":"US","date":"2025-05-08","symbol":"DMRA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.92},{"market":"US","date":"2025-03-19","symbol":"DMRA","fiscalQuarterEnding":"2024/12","expectedEps":-3.12,"name":null,"time":"盘后","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":-5.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1771387200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMRA","date":"2026-03-23","current":-0.149721,"percent":1,"low":-100.260711,"twenty":-100.169461,"median":-94.975827,"eighty":-77.448262,"high":-5.207587,"avg":-82.500658,"sd":28.776013,"marketCap":1092754906},"quantilePoints":[{"date":"2026-03-13","current":-100.260711,"twenty":-100.260711,"median":-100.260711,"eighty":-98.29884,"marketCap":1588530698},{"date":"2026-03-20","current":-72.999835,"twenty":-100.199878,"median":-95.983376,"eighty":-84.763454,"marketCap":1156609382},{"date":"2026-03-23","current":-5.207587,"twenty":-100.169461,"median":-94.975827,"eighty":-77.448262,"marketCap":1092754906}],"updateTime":1774352141339},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMRA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151744301","title":"Galecto Inc旗下Damora计划于2026年中提交DMR-001新药临床试验申请 概念验证数据预计2027年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1151744301","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151744301?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:07","pubTimestamp":1773058034,"startTime":"0","endTime":"0","summary":"生物技术公司Galecto Inc.近日披露其子公司Damora的最新研发进展。根据规划，Damora拟于2026年中期向监管机构提交DMR-001的新药临床试验申请或临床试验授权，该时间表标志着其在纤维化疾病治疗领域的重要里程碑。与此同时，针对DMR-001的概念验证关键数据集预计将在2027年中期揭晓。此次进展凸显了Galecto Inc.通过Damora平台深化其在创新疗法领域的战略布局。若后续研究顺利推进，DMR-001有望为特定纤维化疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139","GLTO"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DMRA\",params:#limit:6,delay:false,,,undefined,":[]}}